2017 Pediatric Rheumatology Symposium

May 17-20, 2017. Houston, Texas.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b [c] d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 55

Celiac Disease in Children Diagnosed with Juvenile Idiopathic Arthritis
Abstract Number: 129

Cell-bound Complement Activation Products Correlate with Disease Activity in Childhood-onset Systemic Lupus Erythematosus
Abstract Number: 126

Challenges in Transitioning Adolescents with Rheumatologic Diseases to Adult Care – The Brazilian Experience
Abstract Number: 108

Characteristics and long-term outcome of children and adolescents with initial diagnosis of Behçet’s disease in a tertiary care center in Brazil
Abstract Number: 85

Characteristics of anti-MDA5 autoantibody-associated Juvenile Dermatomyositis (JDM) in North America
Abstract Number: 152

Characteristics of Patients With Juvenile Idiopathic Arthritis in a US Healthcare Claims Database
Abstract Number: 150

Childhood-onset Takayasu Arteritis Associated with Mutations in CBL
Abstract Number: 107

Children with Relapsing Polychondritis are likely to be seen in the emergency room prior to establishing the diagnosis
Abstract Number: 137

Chromatin Landscapes and Genetic Risk For Juvenile Idiopathic Arthritis
Abstract Number: 88

Clinical Features and Frequency of Biologic use in Patients with Juvenile Dermatomyositis-associated Calcinosis
Abstract Number: 114

Clinical Features and Treatment Outcomes in Down’s Arthropathy
Abstract Number: 109

Clinical features of pediatric Behçet’s disease patients in Japan
Abstract Number: 71

Consensus-based diagnostic approach to systemic juvenile idiopathic arthritis in Germany
Abstract Number: 98

Contraceptive use, Counseling given and the Occurrence of Venous Thrombus Embolism in Adolescent Systemic Lupus Erythematosus
Abstract Number: 96

Correlation and Responsiveness of Cutaneous Lupus Disease Area and Severity Index and Skindex-29 with Cutaneous Childhood Lupus Erythematous
Abstract Number: 93

Corticosteroid Regimen Use in the Pilot Study of Consensus Treatment Plans for Induction Therapy in Childhood Proliferative Lupus Nephritis
Abstract Number: 30

Cross-sectional Analysis of Depression and Medication Non-Adherence in Childhood-onset Systemic Lupus Erythematosus

Jump to: View All • a b [c] d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].